Pharmaceutical Manufacturer Assertio Therapeutics Inc. Agrees
Outcome
OIG enforcement action against Pharmaceutical Manufacturer Assertio Therapeutics Inc. Agrees for false claims, controlled substance. Penalty: $3.6 million.
Details
Pharmaceutical Manufacturer Assertio Therapeutics Inc. Agrees — OIG Enforcement (2026)
OIG took enforcement action against Pharmaceutical Manufacturer Assertio Therapeutics Inc. Agrees in IL in 2026 involving false claims, controlled substance violations in the Independent Pharmacies sector.
Penalty: $3.6 million
Violation types: False Claims, Controlled Substance
Entity type: Pharmacy
Penalty type: Settlement
Location: IL
Source: Pharmaceutical Manufacturer Assertio Therapeutics Inc. Agrees To Pay $3.6M To Resolve Allegations That It Violated The False Claims Act In Connection With Marketing Its Fentanyl Product
How Crucible Prevents This
Crucible's billing compliance controls enforce documentation-to-claims reconciliation, requiring clinical attestation before claims submission and flagging billing patterns that deviate from documented care delivery. Crucible's controlled substance tracking enforces DEA-compliant inventory reconciliation, flags prescribing pattern anomalies, and requires segregation of duties for dispensing and record-keeping.
Don't let this happen to your organization. See how Crucible works.
See How Crucible Works